5 years ago

Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention

Fenton, T., Browning, R., Klingman, K.L., Shapiro, D.E., Strehlau, R., Violari, A., Flynn, P.M., Taha, T.E., Gnanashanmugam, D., Mofenson, L.M., Currier, J.S., Bhosale, R., Theron, G.B., Fiscus, S.A., Coletti, A.S., Fowler, M.G., Mlay, P., Bobat, R., Qin, M., Purdue, L., Owor, M., Chipato, T., Moodley, D., Siberry, G.K., Chi, B.H., IMPAACT 1077BF/1077FF PROMISE Study Team, Basar, M., McIntyre, J., Loftis, A.J., Martinson, F.E.
(N Engl J Med. 2016;375(18):1726–1737) Although triple-drug antiretroviral therapy (ART) has clear benefits for mothers and infants, studies have shown higher rates of adverse pregnancy outcomes with maternal ART than with regimens containing fewer antiretroviral agents. The Promoting Maternal and Infant Survival Everywhere (PROMISE) trial thus compared the relative efficacy and safety of various open-label antiretroviral strategies and their effect on preventing mother-to-child transmission among asymptomatic HIV-infected pregnant women with high CD4 counts (at least 350 cells/mm3).
You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.